Capital Research Discloses 6% Stake in IDEAYA

IDEAYA Biosciences, Inc. received an updated ownership report from Capital Research Global Investors, which reports beneficial ownership of 5,279,675 shares of IDEAYA common stock.

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. received an updated ownership report from Capital Research Global Investors, which reports beneficial ownership of 5,279,675 shares of IDEAYA common stock. This represents 6.0% of the 87,666,408 shares believed to be outstanding as of the reported date.

Capital Research Global Investors has sole power to vote and dispose of all 5,279,675 shares and no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of IDEAYA.

Insights

Equity ownership and governance analyst

Capital Research reports a 6% passive stake in IDEAYA.

Capital Research Global Investors reports beneficial ownership of 5,279,675 IDEAYA Biosciences shares, equal to 6.0% of 87,666,408 shares believed outstanding. The firm holds sole voting and dispositive power over these shares, indicating a concentrated institutional position.

The certification specifies that the position is held in the ordinary course of business and not to change or influence control. That language aligns with a passive institutional investment under Schedule 13G, rather than an activist stance.

As a result, this disclosure mainly informs the market about the presence and size of a significant institutional holder. Any future changes in this stake would be reflected in subsequent beneficial ownership filings if they cross regulatory thresholds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IDEAYA (IDYA) shares does Capital Research Global Investors own?

Capital Research Global Investors reports beneficial ownership of 5,279,675 IDEAYA Biosciences common shares. This stake reflects shares over which it has sole voting and dispositive power, as disclosed in the Schedule 13G/A ownership section.

What percentage of IDEAYA (IDYA) does Capital Research Global Investors hold?

Capital Research Global Investors holds 6.0% of IDEAYA Biosciences’ common stock. This percentage is based on 5,279,675 shares compared with 87,666,408 shares believed to be outstanding, as stated in the ownership disclosure.

Is Capital Research Global Investors an active or passive investor in IDEAYA (IDYA)?

The filing characterizes Capital Research Global Investors as a passive investor. It certifies the IDEAYA shares were acquired and are held in the ordinary course of business, not for changing or influencing control of the company.

Does Capital Research Global Investors share voting power over IDEAYA (IDYA) shares?

No. The filing states Capital Research Global Investors has sole voting power over 5,279,675 IDEAYA shares and shared voting power over zero shares. It also has sole, and no shared, dispositive power over the same amount.

What is the date of the ownership event reported for IDEAYA (IDYA)?

The ownership information relates to an event dated 12/31/2025. That date is identified as the event requiring the filing of the Schedule 13G/A, which reports Capital Research Global Investors’ 6.0% beneficial ownership position.

Who signed the IDEAYA (IDYA) Schedule 13G/A for Capital Research?

The Schedule 13G/A was signed by Jae Won Chung, identified as Vice President and Senior Counsel II of Capital Research and Management Company. The signature is dated 02/05/2026, certifying the accuracy of the ownership disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 10:25 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

IDEAYA Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45166A102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45166A102

1

Names of Reporting Persons

Capital Research Global Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,279,675.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,279,675.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,279,675.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IDEAYA Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA 94080
Item 2.
(a)	Name of person filing: Capital Research Global Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 45166A102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,279,675 ** **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 5,279,675 shares or 6.0% of the 87,666,408 shares believed to be outstanding.
(b)	Percent of class: 6.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,279,675
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,279,675
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. SMALLCAP World Fund, Inc.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital Research Global Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	02/05/2026